OrbiMed Advisors LLC's Form 4 filing
Janux Therapeutics, Inc. (JANX) · filed Dec 17, 2021
- Accession no.
- 0000947871-21-001299
- Filed
- Dec 17, 2021, 5:13 PM ET
- Trade date
- Dec 16, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $7.50M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | Director |
| OrbiMed Capital GP VII LLCCIK 0001760648 | Director |
| OrbiMed Genesis GP LLCCIK 0001808744 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 16, 2021 | Common Stock | SSaleDisposed | −356,800 | $19.07 | −$6,804,176 | 2,403,566 | Indirect | Duplicate filing |
| Dec 16, 2021 | Common Stock | SSaleDisposed | −36,500 | $19.07 | −$696,055 | 245,898 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.